Recommendation of the Immunization Practices Advisory Committee (ACIP) Prevention and Control of Influenza
These recommendations extensively revise previous influenza vaccine recommendations of the Immunization Practices Advisory Committee (ACIP) (superseding MMWR 1983;32:333-7) and provide information on the vaccine and antiviral agent available for control of influenza in the 1984-1985 influenza season and on target groups for which special influenza control programs are recommended.
Influenza viruses have continually demonstrated an ability to cause major epidemics of respiratory disease. Typical influenza illness is characterized by abrupt onset of fever, sore throat, and nonproductive cough and, unlike many other common respiratory infections, can cause extreme malaise lasting several days. More severe disease can result from invasion of the lungs by influenza virus (primary viral pneumonia) or by secondary bacterial pneumonia. High attack rates of acute illness and the frequent occurrence of lower respiratory tract complications usually result in dramatic rises in numbers of visits to physicians' offices and to hospital emergency rooms. Furthermore, influenza frequently infects individuals, who, because of their ages or underlying health problems, are poorly able to cope with the disease and often require medical attention, including hospitalization. Such persons are considered to be medically at "high risk" in epidemics. ln one recent study, for example, hospitalization rates for adults with "high-risk" medical conditions increased during major epidemics by about twofold to fivefold in different age groups, reaching a maximum rate of about 800 excess hospitali- zations per 100,000 high-risk persons.
A further indication of the impact of influenza epidemics is the significant elevation of mortality that often occurs. Such excess mortality is attributed not only to the direct cause of influenza pneumonia but also to an increase in deaths from cardiopulmonary disease. Epidemics have been associated with excess deaths of 10,000 persons or more 15 times from 1957 to 1982; excess mortality again exceeded the epidemic threshold during the 1982-1983 influenza season.
The greatest impact of influenza is normally seen when new strains appear against which most of the population lacks immunity. In these circumstances (e.g., 1957 and 1968), pandemics occur, and a quarter or more of the U.S. population has been affected over a period of 2-3 months.
Because of the increasing proportion of elderly persons in the U.S. population and because age and its associated chronic diseases are risk factors for severe influenza illness, the future toll from influenza may increase, unless control measures are used more vigorously than in the past. Other populations at high risk for influenza-related complications are also increasing, due, for example, to the success of intensive-care units for neonates, better management of diseases, such as cystic fibrosis, and better survival rates for organ-transplant recipients. This statement discusses the presently available medical-control measures, immunoprophylaxis with vaccines, and prophylaxis or therapy with the antiviral drug, amantadine.
OPTIONS FOR THE CONTROL OF INFLUENZA
For about 20 years, efforts to reduce the impact of influenza in the United States have been aimed primarily at immunoprophylaxis of persons at greatest risk of serious illness or death. Observations during influenza epidemics indicate that most influenza-related deaths occur among: (1) persons older than 65 years of age and (2) persons with chronic, underlying disorders of the cardiovascular, pulmonary, and/or renal systems, as well as those with metabolic diseases (including diabetes mellitus), severe anemia, and/or compromised immune function. Recommendations listed below apply mainly to these high-risk groups. In addition, measures are described that apply to other individuals or groups under special circumstances. Influenza-control options should also be made available to individuals who wish to reduce their chances of acquiring influenza infection or to reduce the severity of disease.
Prophylaxis is likely to be achieved with greatest cost-effectiveness by vaccinating individuals for whom infection may have the most severe consequences and for whom there is a higher-than-average potential for infection. In addition, vaccination can best be organized when such high-risk individuals routinely have contact with the health-care delivery system for causes other than acute respiratory infection before the influenza season, thereby permitting vaccine administration without special visits to doctors' offices or clinics. Other indications for prophylaxis (whether with vaccine or antiviral drugs) include the strong desire of any person to avoid a preventable illness.
The presently available specific therapy for influenza A--amantadine hydrochloride (Symmetrel((R)))--is most likely to be beneficial for individuals who seek medical attention promptly due to the abrupt onset of an acute respiratory infection with troublesome symptoms during an influenza A epidemic. For high-risk individuals for whom influenza vaccine has not been used or has not prevented infection, amantadine therapy should be effective in reducing the severity of disease.
INACTIVATED INFLUENZA VACCINE
Use of inactivated influenza vaccine is the single most important measure in preventing and/or attenuating influenza infection. Potency of present vaccines is such that nearly all vaccinated young adults develop hemagglutination-inhibition antibody titers that are likely to protect them against infection by strains like those in the vaccine and, often, by related variants that emerge. The elderly, the very young, and patients with certain chronic diseases may develop lower post-vaccination antibody titers than young adults. Under these circumstances, however, influenza vaccine may be more effective in preventing lower respiratory tract involvement or other complications of influenza than in preventing infection and involvement of the upper respiratory tract. Influenza vaccine will not, of course, prevent primary illnesses caused by other respiratory pathogens.
Annual vaccination against influenza has been recommended since 1963 for individuals at high risk of lower respiratory tract complications and death following influenza infection, i.e., the elderly and persons with chronic disorders of the cardiovascular, pulmonary, and/or renal systems, metabolic diseases, severe anemia, and/or compromised immune function. These groups have been identified primarily by reviews of death certificate data, supported by hospital-based or population-based studies. Each group encompasses patients along a continuum of underlying general health. In other words, within each broadly defined high-risk category, some persons may be more likely than others to suffer severe complications from influenza infection.
Investigations of influenza outbreaks in nursing homes, for example, have demonstrated attack rates as high as 60%, with case-fatality ratios as high as 30% or more. Chronic diseases and other debilitating conditions are common among nursing-home residents, and spread of infection can often be explosive in such relatively crowded and closed environments. Recent retrospective studies of noninstitutionalized patients also suggest that chronic, underlying diseases, particularly those that affect the cardiovascular and pulmonary systems, may contribute more to the severity of illness than age alone. Since influenza infections are also known to invoke abnormalities in gas exchange and peripheral airways dysfunction in adults, children with compromised pulmonary function, including those with cystic fibrosis, chronic asthma, and bronchopulmonary dysplasia, and neonates in intensive-care units may also be at higher risk of severe illness, although firm evidence is lacking. Children with congenital heart disease may also be considered at high risk, since respiratory viruses in general often produce severe infections in this population.
Target Groups for Vaccination
Vaccine composition and doses are given in Table 1. Guidelines for use of vaccine are given below for different segments of the population:
High-Priority Target Groups: Annual vaccination with inactivated influenza vaccine is considered the single most important measure in preventing or attenuating influenza infection and is strongly recommended for the above groups. In most past years, only 20% of the groups defined as high risk on the basis of medical condition or age received influenza vaccine in any given year. Increased effort must be made to immunize persons in high-risk groups, particularly those in the highest-priority target groups (1 above).
As an initial step, the ACIP recommends that infection control programs in institutions for the aged or chronically ill have as their goal the achievement of no less than 80% vaccination rates for the residents. Hospitals and physicians should have a similar objective for vaccinating patients with severe cardiopulmonary disorders and for vaccinating medical personnel who have the greatest potential to introduce influenza virus into high-risk hospital settings (2 above). Wherever possible, efforts should also be made to vaccinate persons at moderately increased risk (3 above). This latter objective often requires that active promotion of influenza vaccine be made by individual physicians who practice outside organizations that can set administrative guidelines and procedures for their professional staff. Establishment of physicians' office and clinic systems for influenza vaccination activities are essential to assist the physician in providing vaccine.
General Population: Physicians should administer vaccine to any persons in their practices who wish to reduce their chances of acquiring influenza infection. Persons who provide essential community services, such as employees of fire and police departments, and health-care personnel are not considered to be at increased occupational risk of serious influenza illness but may be considered for vaccination programs designed to minimize the possible disruption of essential activities that can occur during severe epidemics.
Pregnant Women: Pregnancy has not been demonstrated to be a risk factor for severe influenza infection, except in the largest pandemics of 1918-1919 and 1957-1958. Influenza vaccine is considered generally safe for pregnant women. Nonetheless, when vaccine is given during pregnancy, waiting until the second or third trimester is a reasonable precaution to minimize any concern over the theoretical possibility of teratogenicity.
Persons Who Should Not Be Vaccinated: Inactivated influenza vaccine should not be given to persons who have anaphylactic sensitivities to eggs (see Side Effects and Adverse Reactions). Persons with acute febrile illnesses normally should not be vaccinated until their temporary symptoms have abated.
Strategies for Implementing Influenza Vaccine Recommendations
Influenza vaccine should normally be obtained to use during the fall. More effective programs for giving influenza vaccine are needed in nursing homes and other chronic-care facilities, in physicans' offices, and in hospital settings. Adults and children in high-priority target groups who do not reside in nursing homes or other chronic-care facilities should be given influenza vaccine at the time of regular medical follow-ups in the fall. Those not scheduled for regular medical appointments in the fall should be notified by their medical offices or clinics to come in specifically to receive influenza vaccine. Physicians responsible for care of hospitalized patients should, during the fall, consider administering influenza vaccine to patients with high-risk conditions before the patients are discharged.
These and other programs to annually vaccinate target groups require planning well in advance and should, whenever possible, be completed before the beginning of the influenza season. However, vaccine can be given right up to the time influenza virus activity is documented and even thereafter, although temporary chemoprophylaxis may be indicated in these situations (see amantadine recommendations below).
Influenza A viruses are classified into subtypes on the basis of two antigens: hemagglutinin (H) and neuraminidase (N). Three subtypes of hemagglutinin (H1, H2, H3) and two subtypes of neuraminidase (N1, N2) are recognized among influenza A viruses that have caused wide-spread human disease. Immunity to these antigens, especially hemagglutinin, reduces the likelihood of infection and the severity of disease if infection does occur. However, there may be sufficient antigenic variation (antigenic drift) within the same subtype over time, so that infection or vaccination with one strain may not induce immunity to distantly related strains of the same subtype. Although influenza B viruses have shown much more antigenic stability than influenza A viruses, antigenic variation does occur. As a consequence, the antigenic characteristics of current strains provide the basis for selecting virus strains included in the vaccine.
Based on the most recent epidemiologic and laboratory data (reported periodically in MMWR during the 1983-1984 influenza season), it is antici- pated that strains prevalent in 1984-1985 will be closely related to A/Philippines/2/82 (H3N2), A/Chile/1/83 (H1N1), and B/USSR/100/83. Therefore, these strains will be included in the vaccine for use during the 1984-1985 season (Table 1). The type A(H1N1) and type B components represent changes from the 1983-1984 vaccine, which should be discarded.
Side Effects and Adverse Reactions
Vaccines used in recent years have generally been associated with only a few reactions; fewer than one-third of vaccinees have been reported to develop local redness or induration for 1 or 2 days at the site of injection.
Systemic reactions have been of two types:
Simultaneous Pneumococcal Vaccination
There is considerable overlap in the target groups for influenza vaccination and those for pneumococcal vaccine. Pneumococcal vaccine and influenza vaccine can be given at the same time at different sites without increased side effects, but it should be emphasized that, whereas influenza vaccine is given annually, pneumococcal vaccine should be given only once to adults. Detailed immunization records, which should be provided to each patient, will help ensure that additional doses of pneumococcal vaccine are not given.
ANTIVIRAL AGENT: AMANTADINE
The only drug currently available for the specific prophylaxis and therapy of influenza virus infections is amantadine hydrochloride (Symmetrel((R))), which appears to interfere with the uncoating step in the virus replication cycle. The drug also reduces virus shedding. Amantadine is 70%-90% effective in preventing illnesses caused by circulating strains of type A influenza viruses (it is not effective against type B influenza). When administered within 24-48 hours after onset of illness, amantadine has been shown to reduce the duration of fever and other systemic symptoms with a more rapid return to routine daily activities and improvement in peripheral airway function. Since it may not prevent actual infection, persons who take the drug may still develop immune responses that will protect them when exposed to antigenically related viruses.
While considerable evidence shows that amantadine chemoprophylaxis is effective against influenza A, under most circumstances it should not be used in lieu of vaccination, because it confers no protection against influenza B, and patient compliance could be a problem for continuous administration throughout epidemic periods, which generally last 6-12 weeks.
Prophylaxis: Specific circumstances for which amantadine prophylaxis is recommended include the following:
Therapy: Since vaccine efficacy is less than 100%, amantadine should be considered for therapeutic use, particularly for persons in the high-risk groups if they develop an illness compatible with influenza during a period of known or suspected influenza A activity in the community. The drug should be given within 24-48 hours of onset of illness and should be continued until 48 hours after resolution of signs and symptoms.
Persons who should not be given amantadine: Particular caution should be exercised for persons under 1 year of age or persons of any age with impaired renal function (see below).
The usual dosage of amantadine is 200 mg/day. Splitting the dose into 100 mg twice daily may reduce the frequency of side effects. Dosages for children and for persons with reduced renal function are given in Table 2.
Side Effects and Adverse Reactions
Five percent to 10% of otherwise healthy adults taking amantadine have reported side effects, such as insomnia, lightheadedness, irritability, and difficulty concentrating. These and other side effects (see package insert) may be more pronounced among patients with underlying diseases, particularly those common among the elderly; provisions for careful monitoring are needed for these individuals so that adverse effects may be recognized promptly and the drug reduced in dosage or discontinued, if necessary. Since amantadine is not metabolized, toxic levels will occur when renal function is sufficiently impaired.
Under special circumstances, supplementary control measures may be useful in further limiting the spread of influenza. Influenza is known to cause nosocomial infection, and a number of measures, including isolation, cohorting of patients and personnel, limiting visitors, and avoiding elective admissions and surgery during an influenza outbreak, have all been suggested to limit further transmission, However, the effectiveness of most of these measures has not been conclusively demonstrated. Schools or classrooms have been closed occasionally when explosive outbreaks have occurred. The effect of this measure on virus transmission has not been established.
SELECTED BIBLIOGRAPHY Barker WH, Mullooly JP. Influenza vaccination of elderly persons. Reduction
in pneumonia and influenza hospitalizations and deaths. JAMA 1980;244:2547-9. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined
adult population. Am J Epidemiol 1980;112:798-811. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics:
implications for prevention. Arch Intern Med 1982;142:85-9. Consensus development conference panel. Amantadine: does it have a role in
the prevention and treatment of influenza? A National Institutes of Health Consensus Development Conference. Ann Intern Med 1980;92:256-8. Dowdle WR, Coleman MT, Gregg MB. Natural history of influenza type A in the
United States, 1957-1972. Prog Med Virol 1974;17:91-135. Eickhoff TC. Immunization against influenza: rationale and recommendations.
J Infect Dis 1971;123:446-54. Fedson DS, Kessler HA. A hospital-based influenza immunization program,
1977-78. Am J Public Health 1983;73:442-5. Galasso GJ, Tyeryar FJ Jr, Cate TR, et al., eds. Clinical studies of
influenza vaccines--1976. J Infect Dis 1977;136(suppl):S341-S742. Glezen WP. Serious morbidity and mortality associated with influenza
epidemics. Epidemiol Rev 1982;4:25-44. Horadam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadine
hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981;94:454-8. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barre syndrome in
the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 1982;248:698-700. Kilbourne ED, ed. The influenza viruses and influenza. New York: Academic
Press, 1975. Leneman F. The Guillain-Barre syndrome: definition, etiology, and review of
1,100 cases. Arch Intern Med 1966;118:139-44. Mufson MA, Krause HE, Tarrant CJ, Sciffman G, Cano FR. Polyvalent pneumo-
coccal vaccine given alone and in combination with bivalent influenza vaccine. Proc Soc Exp Biol Med 1980;163;498-503. Nolan TF Jr, Goodman RA, Hinman AR, Noble GR, Kendal AP, Thacker SB. Morbid-
ity and mortality associated with influenza B in the United States, 1979-1980. A report from the Center for Disease Control. J Infect Dis 1980;142:360-2. Parkman PD, Galasso GJ, Top FH Jr, Noble GR. Summary of clinical trials of
influenza vaccines. J Infect Dis 1976;134:100-7. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syn-
drome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23. Schonberger LB, Hurwitz ES, Katona P, Holman RC, Bregman DJ. Guillain-Barre
syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol 1981;9(suppl):31-8. Wright PF, Dolin R, La Montagne JR. Summary of clinical trials of influenza
vaccines-II. J Infect Dis 1976;134:633-8.
Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.
Page converted: 08/05/98
This page last reviewed 5/2/01